Table 3.
Anticancer activity in vitro.
| Compounds | EC50 (µM) * | |
|---|---|---|
| K-562 | MCF-7 | |
| 3a | >50 | >50 |
| 3c | >50 | >50 |
| 3d | >50 | >50 |
| 4a | >50 | >50 |
| 4c | 71 ± 2 | 79 ± 1 |
| 4d | >50 | >50 |
| 4e | 40 ± 8 | 70 ± 5 |
| 4f | >25 | >25 |
| 4g | 51 ± 5 | 75 ± 2 |
| 4h | >12 | >12 |
| 4i | >50 | >50 |
| 4j | >25 | >25 |
| 4k | >50 | >50 |
| 4l | >50 | >50 |
| 5a | 11 ± 1 | 17 ± 6 |
| 5b | 40 ± 5 | 24 ± 4 |
| 5c | 59 ± 4 | 17 ± 1 |
| 5d | 19 ± 6 | 12 ± 1 |
| 5e | 29 ± 6 | 27 ± 6 |
| 5f | 13 ± 1 | 10 ± 2 |
| 5g | 8.7 ± 1.3 | 7.2 ± 2.9 |
| 5h | 14 ± 1 | 10 ± 1 |
| 5i | 19 ± 8 | 15 ± 5 |
| 5j | 36 ± 11 | 23 ± 5 |
| 5k | 4.2 ± 1.1 | 3.2 ± 0.9 |
| 5l | >50 | >50 |
| 6a | 8.7 ± 1.2 | 18 ± 3 |
| 6c | 60 ± 8 | 17 ± 4 |
| 6d | >50 | >50 |
| 6e | 24 ± 1 | 34 ± 6 |
| 6f | 82 ± 7 | 39 ± 3 |
| 6g | 15 ± 3 | 20 ± 2 |
| 6h | 59 ± 12 | 45 ± 6 |
| 6i | 67 ± 18 | 43 ± 9 |
| 6j | 14 ± 1 | 21 ± 2 |
| 6k | >50 | >50 |
| 6l | >50 | >50 |
| 7c | 82 ± 10 | 57 ± 7 |
| 7d | 41 ± 4 | 16 ± 1 |
| 7e | >50 | 38 ± |
| 7f | 81 ± 17 | 69 ± 7 |
| 7g | 29 ± 13 | 11 ± 6 |
| 7h | >50 | >50 |
| 7i | 6.4 ± 1.1 | 5.3 ± 1.1 |
| 7j | 0.8 ± 0.2 | 2.6 ± 0.3 |
| 7k | 5.1 ± 0.7 | 1.8 ± 0.8 |
| 7l | 8.3 ± 1.4 | 7.7 ± 0.9 |
| 9t | >50 | >50 |
| 9u | >50 | 45 ± 4 |
| 9w | >50 | 36 ± 9 |
| 9z | >50 | >50 |
| 13 | 94 ± 6 | 48 ± 2 |
| 14 | 0.9 ± 0.2 | 1.4 ± 0.1 |
| norchelerythrine | >100 | >100 |
| isodecarine | >100 | >100 |
| NK-109 | 1.0 ± 0.1 | 4.6 ± 0.6 |
| chelerythrine | 8.6 ± 1.8 | 5.9 ± 0.5 |
| sanguinarine | 2.2 ± 0.2 | 2.0 ± 0.2 |
| cisplatin | 4.7 ± 0.4 | 11 ± 1 |
* Values are means of triplicates and indicate concentration that kills 50% of cells during a three-day cultivation.